Here's the coronavirus-related news from this week that you should know.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), has infected an estimated 39,068,667 individuals worldwide at publishing time, and nearly 8 million Americans. The latest COVID-19-related news includes the FDA approval of remdesivir for the treatment of COVID-19, and the recent partnership between the Trump administration, CVS, and Walgreens in facilitating the distribution of COVID-19 vaccines to long term care facilities (LTCFs).
Here’s a roundup of the latest coronavirus-related news:
Under normal circumstances, pharmacists are a critical component of vaccine uptake, as well as a trusted resource for patients looking to gain information and make informed decisions about the risks and benefits of vaccination. Now, with the “twindemic” of the COVID-19 and influenza season underway, the pharmacy workforce, more than ever, are positioned to support uptake of flu and COVID-19 vaccines. Read our coverage from the National Community Pharmacists Association 2020 Annual Convention for more.
Officials with the FDA have approved Gilead’s remdesivir (Veklury) for the treatment of COVID-19, making it the first FDA-approved treatment for the disease, the company announced.
In a new guidance, the Department of Health and Human Services (HHS) offered clarification on the requirements for pharmacy interns and technicians to be able to administer childhood vaccines and COVID-19 vaccines once available.
CVS Health is hiring more than 10,000 full-time and part-time pharmacy technicians to meet the demand for flu vaccinations and, in the future, COVID-19 vaccinations.
HHS and the Department of Defense recently announced a new agreement with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of LTCFs nationwide.